← Research library

Ladasten in neurasthenia and somatogenic asthenia: safety and therapeutic efficacy

Randomized study in people · 2009

What was studied
40 patients: 20 per diagnosis, randomized within diagnosis to active treatment or placebo (10 per cell)
Main finding
Single-blind, stratified randomized comparison reported symptom improvement over 28 days. Mild restlessness during treatment and transient dizziness after withdrawal were reported.

Reported findings and study design

40 patients: 20 with each of two diagnoses, randomized within diagnosis to active drug or placebo; four cells of ten. Single-blind, 28-day treatment and seven-day post-treatment observation.

Population or model 40 patients: 20 per diagnosis, randomized within diagnosis to active treatment or placebo (10 per cell)

Results · Previously reviewed publisher methods and harms narrative; numerical image tables not newly extracted
MeasureResultComparison, timing and statistics
Symptom improvementReported over 28 daysNumerical table values were not transcribed in the prior review
Harms describedMild restlessness during treatment; transient dizziness after withdrawalEvent denominators not supplied in the checked narrative

Existing publisher methods and narrative review used. Table recovery is deferred; possible overlap with other 2009 reports remains unresolved.

Source for these results ↗ · Reviewed 2026-10-29

Study limitations and source details

Study limitations

  • Four small groups; multiple symptom outcomes.
  • Seven-day post-treatment observation cannot establish long-term dependence or safety.
  • Overlap with other 2009 Ladasten reports remains unresolved; do not sum cohorts.

Related publications may describe some of the same participants or experiments.

Source details

Publisher HTML article

Publisher methods, results and harms narrative checked; image tables not independently transcribed.

Methods, results and harms narrative

Sources checked

Citation

Randomized trialFull text available

A. S. Avedisova, T. Yu. Kulikova, O. I. Mikhailova. Ladasten in neurasthenia and somatogenic asthenia: safety and therapeutic efficacy Mental Disorders in General Medicine. 2009(1):57–60

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards